STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2660 by analyst upside · 2026-06-27
LH
Labcorp Holdings Inc.
Healthcare · Market Cap $22B · P/E 23.6x
ANALYST PRICE TARGET
+14.2%
implied upside to consensus target
Current Price $271.47
Consensus Target $310.12
Bull Target $340.0
Bear Target $270.0
Analysts Covering 17
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
11
Hold
4
Sell
0
52-Week Low $241.81
52-Week High $293.72
YTD Return +8.4%
FUNDAMENTALS
Market Cap $22B
P/E Ratio (TTM) 23.6x
Forward P/E 14.0x
EPS (TTM) $11.51
PEG Ratio 1.12
Dividend Yield 1.06%
Revenue (TTM) $14.1B
Profit Margin 6.7%
52-WEEK RANGE
52-Week Low $241.81
52-Week High $293.72
Current Price $271.47
Bear Target $270.0
Bull Target $340.0
● Now $271.47 ● Target $310.12
TRADING DATA
Avg Volume 642K
YTD Return +8.4%
Analyst Count 17
Consensus Buy
Upside to Target +14.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Labcorp Holdings Inc. (LH) is currently trading at $271.47 with a Wall Street consensus price target of $310.12, implying potential upside of 14.2% over the next 12 months. 17 analysts currently cover LH, with a consensus rating of Buy — 76% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $340.0, while the most cautious has a target of $270.0.

LH operates in the Healthcare sector with a market capitalisation of $22B. The stock is up 8.4% year-to-date and is currently trading near the upper end of its 52-week range of $241.81 – $293.72.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group — Reiterated
Outperform → Outperform 2026-04-08 Building track record
Piper Sandler — Reiterated
Neutral → Neutral 2026-02-24 14% win rate (7 calls)
JP Morgan — Reiterated
Overweight → Overweight 2026-02-18 43% win rate (7 calls)
Baird — Reiterated
Outperform → Outperform 2026-02-18 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-02-06 43% win rate (7 calls)
JP Morgan — Reiterated
Overweight → Overweight 2025-11-07 43% win rate (7 calls)
UBS — Reiterated
Buy → Buy 2025-10-29 33% win rate (6 calls)
UBS — Reiterated
Buy → Buy 2025-10-17 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →